The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Video navigation menu
- Increased lifetime risk for CHD in diabetic patients 00:20
- Can intensive glucose control address residual vascular risk in diabetic patients? 01:40
- Effect of LDL-c lowering on CV risk reduction in patients with T2DM 02:15
- Role of inflammation in T2DM 05:32
- Effect of anti-inflammatory interventions in CV patients with diabetes 08:17
This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.